An alternative hypothesis to involvement of intestinal P-glycoprotein as the cause for digoxin oral bioavailability enhancement by talinolol.
Chiou
W L
WL
Ma
C
C
Chung
S M
SM
Wu
T C
TC
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000378:metabolism*; D000284:Administration, Oral; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D001682:Biological Availability; D002316:Cardiotonic Agents / Q000493:pharmacokinetics*; D004077:Digoxin / Q000493:pharmacokinetics*; D004347:Drug Interactions; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects / Q000502:physiology; D007413:Intestinal Mucosa / Q000378:metabolism*; D011412:Propanolamines / Q000494:pharmacology*
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000319:Adrenergic beta-Antagonists; D002316:Cardiotonic Agents; D011412:Propanolamines; C011550:talinolol; D004077:Digoxin